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Although antiretroviral therapy (ART) significantly improves the survival status and quality of
life among human immunodeficiency virus (HIV)-infected children, loss to follow-up (LTFU)
from HIV-care profoundly affecting the treatment outcomes of this vulnerable population.
For better interventions, up-to-date information concerning LTFU among HIV-infected chil-
dren on ART is vital. However, only a few studies have been conducted in Ethiopia to
address this concern. Thus, this study aims to identify the predictors of LTFU among HIV-
infected children receiving ART at Debre Markos Referral Hospital.
Methods
An institution-based retrospective follow-up study was done among 408 HIV-infected chil-
dren receiving ART at Debre Markos Referral Hospital between 2005 and March 15, 2019.
Data were abstracted from the medical records of HIV-infected children using a standard-
ized data abstracted checklist. We used Epi-Data Version 3.1 for data entry and Stata Ver-
sion 14 for statistical analysis. The Kaplan-Meier survival curve was used to estimate the
survival time. A generalized log-rank test was used to compare the survival curves of differ-
ent categorical variables. Finally, both bi-variable and multivariable Cox proportional hazard
regression models were used to identify the predictors of LTFU.
Results
Of 408 HIV-infected children included in the final analysis, 70 (17.1%) children were LTFU
at the end of the study. The overall incidence rate of LTFU among HIV-infected children was
found to be 4.5 (95%CI: 3.5–5.7) per 100-child years of observation. HIV-infected children
living in rural areas (AHR: 3.2, 95%CI: 2.0–5.3), having fair or poor ART drug adherence
(AHR: 2.3, 95%CI: 1.4–3.7), children started ART through test and treat approach (AHR:
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2.7, 95%CI: 1.4–5.5), and children started protease inhibiter (PI)-based ART regimens
(AHR: 2.2, 95%CI: 1.1–4.4) were at higher risk of LTFU.
Conclusion
This study found that one in every six HIV-infected children lost form ART follow-up. HIV-
infected children living in rural areas, having fair or poor ART drug adherence, started ART
based on test and treat approach, and taking PI-based ART regimens were at higher risk of
LTFU.
Introduction
Though the concept of “child at risk” highly varies across the continents, in Africa, it com-
monly refers to socially disadvantaged children, including human immunodeficiency virus
(HIV) exposed infants [1]. HIV is a global challenge for humankind’s survival, as Sub-Saharan
Africa (SSA) is profoundly affected. Globally, an estimated 1.7 million children (age<15 years)
were living with HIV in 2018 [2]. In 2014, 87% of new HIV infections and 86% of AIDS-
related deaths among children were from SSA [3, 4]. Ethiopia is one of the SSA countries with
a high HIV prevalence; nearly 62,000 children were living with HIV in 2017 [5, 6]. Antiretrovi-
ral therapy (ART) improves the survival status and quality of life among HIV-infected children
through viral load suppression and increasing CD4 counts [7]. ART dug must be taken contin-
uously and on a daily base to be effective [8]. Otherwise, patients could develop treatment fail-
ure and end-up with death in the early ART phase [5].
A systematic review found that about 5–29% of the children living HIV under the age of 10
lost from ART or died within the first one year of ART initiation worldwide in 2011 [9].
Another study from Asia and Africa reported that loss to follow up (LTFU) among HIV-
infected children was reported as low of 4.1% in Asia and as high of 21.8% in West Africa [10].
In SSA, the proportion of LTFU among HIV-infected children after two years of ART initia-
tion ranged from 9% in Southern Africa to 21.8% in West Africa [10]. As per report of previ-
ous studies, LTFU among HIV-infected children in Ethiopia was ranged from 5.9% [11] to
15% [12].
The Sustainable Development Goals (SDGs) are targeted to end the epidemic of HIV/AIDS
by 2030 [13, 14]. Retention in ART care is a key strategy to achieve this ambitious goal [15]. In
this regard, different interventions have been implemented nationally and internationally. For
example, a short message service (SMS) to remind HIV-patients who missed their appoint-
ments has been implemented in Malawi, Kenya, South Africa, Mozambique, Zimbabwe,
Ruanda, and Zambia [16]. The World Health Organization (WHO) also recommends that
age-appropriate disclosure and caregivers’ regular support are essential to improve retention
in ART care [5]. The orphans and vulnerable children (OVC) program in Africa, in collabora-
tion with health care workers, is working persistently to trace individuals lost from HIV-care
[17]. The Ethiopian government has also implemented adherence support through phone calls
to trace patients lost from ART care [18].
The most commonly reported contributing factors for LTFU among HIV-infected children
are: lack of caregivers’ contact information, fear of stigma, forgetfulness, scheduling conflict,
lack of access to transportation, privacy concerns, not disclosing HIV-status, weak follow-up
at the ART clinic, advanced WHO clinical disease stage, malnutrition, and younger age [19,
20]. Similarly, the common risk factors increasing LTFU among HIV-infected Ethiopian
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children are far from health institutions, lack of access to transportation, fear of stigma, not
disclosing HIV-status, bedridden status, and lack of understanding as ART is a lifelong medi-
cation [21, 22].
Though discontinuation from ART care among children in Ethiopia is a serious public
health concern, to our knowledge, only a few studies have been conducted to explore this
problem. Therefore, this study aims to assess LTFU among HIV-infected children receiving
ART at Debre Markos Referral Hospital. The results of this study will help policymakers and
program planners working in the area of HIV/AIDS to design appropriate interventions in
reducing LTFU in this vulnerable population. This study will also serve as an input for further
prospective observational or interventional studies.
Methods
Study design, period, and setting
An institution-based retrospective follow-up study was conducted at Debre Markos Referral
Hospital between 2005 and March 15, 2019. Debre Markos town is found 300 km from Addis
Ababa, the capital city of Ethiopia. The town has one referral hospital and three public health
centers. The hospital serves for more than 3.5 million people in East Gojjam Zone and neigh-
boring Zones. It has been providing ART care and follow-up services since 2005. Currently,
the ART clinic has two medical doctors, six nurses, three data clerks, one porter, one cleaner,
five case managers, four CDC contract employees, and six adherence supporters. The hospital
uses standardized monitoring and follow-up forms, adopted from the Ethiopian ART guide-
line. A total of 466 HIV-infected children on ART have been recorded since 2005. Of these,
326 children have an active monthly ART follow-up.
Study participants
The records of all HIV-infected children, whoever started ART at Debre Markos Referral Hos-
pital, were the source population. The records of all HIV-infected children receiving ART
between 2005 to March 15, 2019, and whose charts were available during the data collection
period were our study population. All HIV-infected children who had at least one month of
ART follow-up between 2005 and March 15, 2019 were included. Whereas, children who had
incomplete baseline records (i.e., CD4 count, WHO stages, CPT, IPT, and hemoglobin level),
unknown outcomes, and transferred in from other health institutions without baseline infor-
mation were excluded.
Sample size and sampling procedures
This study included all HIV-infected children’s records ever started ART between 2005 and
March 15, 2019. First, the files of all HIV-infected children ever started ART between 2005 and
March 15, 2019 were sorted by data collectors. Second, children who met the above-mentioned
inclusion criteria were isolated. Third, after excluding all incomplete records, a total of 408
HIV infected children records were included in the final analysis. Lastly, data across 14 years
were collected from the charts of each enrolled child.
Data collection procedure and quality control
The data extraction checklist was adapted from a standardized ART intake and follow-up
forms currently used in the ART clinic of Debre Markos Referral Hospital. The most recent
clinical and laboratory tests at ART initiation were considered as baseline information. How-
ever, if pre-treatment laboratory tests were not recorded at ART initiation, laboratory tests
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done within the first month of ART initiation were considered as baseline information. In the
case of two laboratory tests done in the first month of ART, the most recent laboratory value
was taken as baseline. Before data collection, the consistency between the data extraction
checklist and the recording system was cheeked by taking some randomly selected charts, and
necessary amendments were made. Three nurses currently working in the ART clinic of Debre
Markos Referral Hospital were recruited as data collectors. Moreover, the data extraction
checklist was carefully prepared from a standardized ART intake and follow-up forms to main-
tain data quality. Furthermore, training for data collectors and supervisor about the objectives,
significances, and variables of the study was given. Lastly, the supervisor and principal investi-
gators carefully monitored the completeness and consistency of the whole data collection
process.
Variables of the study
The dependent variable was the time to LTFU among HIV infected children after ART initia-
tion. The independent variables were socio-demographic variables, clinical characteristics and
laboratory tests, ART and other medications-related variables, and nutritional variables.
Socio-demographic variables were age of the child, sex of the child, caregivers’ age, caregivers’
residence, marital status of the caregiver, family size, educational status of the caregiver, care-
givers’ relation for the child, and religion. Clinical characteristics and laboratory tests were
WHO clinical staging, CD4 count/percentage, Hgb level, viral load, functional or developmen-
tal status, and baseline OIs. ART and other medications-related variables included baseline
ART regimens, duration of ART, ART side effects, regimen change, treatment failure, taking
IPT, taking CPT, and adherence to ART. Nutritional status included weight for age (W/age),
height for age (H/age), and weight for height (W/height).
Definition of variables
LTFU was recorded when HIV infected children missed their appointments from one month
to three months [5].
Censored was considered when HIV-infected children had died, formally transferred to
other health institutions, or still alive and on ART at the end of the study.
ART Adherence was classified as good, fair, and poor. Good was recorded when the child
took� 95% or missed� three pills of monthly dose. Fair was recoded when the child took 85–
94% or missed four to eight pills of monthly dose. Finally, poor was recorded when the child
took <85% or missed� nine pills of monthly dose.
Children who had CD4 cell counts < 1500/mm3 or 25% for age< 12 months, CD4 cell
counts < 750/mm3 or < 20% for age 12–35 months, CD4 cell counts < 350/mm3 or < 15%
for age 36–59 months, and CD4 cell counts < 200/mm3 or < 15% for age� 60 months were
classified as CD4 counts or percentage (%) below the threshold [23].
Child developmental status was classified as appropriate (able to attain milestones for
age), delayed (failure to attain milestones for age); and regressed (loss of what has been
attained for age). According to the recent Ethiopian ART guideline, developmental status has
the following components: language, psychosocial, fine and gross motor skills, and cognition
[5].
Weight for Age (W/Age) Z-score< -2 SD, Height for Age (H/Age) Z-score < -2 SD and
Weight for height (W/H) Z-score < -2 SD were considered to represent moderate under-
weight, stunting, and wasting respectively [24, 25].
W/Age Z-score < -3 SD, H/Age Z-score < -3 SD, and W/H Z-score < -3 SD were consid-
ered to represent severe underweight, stunting, and wasting respectively [24, 25].
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Data processing and analysis
We used EPI-Data Version 3.1for data entry and Stata Version 14 for analysis. The children’s
Z-scores (WAZ, HAZ, and WHZ/BAZ) were generated using WHO Anthro-Plus Version 1.04
and ENA smart software. Descriptive statistics for categorical variables were visualized using
tables and graphs. Summary results of continuous variables were described using the measure
of central tendency (mean or median) and dispersion (standard deviation or interquartile
range). The Kaplan-Meier survival plot was used to estimate the survival time after ART initia-
tion. A Generalized log-rank test was used to compare the survival curves between categorical
variables. The necessary assumption of Cox-proportional hazard model was assessed using
Schoenfeld residual test and log-log plot. We used the cox-Snell residuals test to check model
fitness. Variables with p-values� 0.25 in the bi-variable analysis were fitted into the multivari-
ate analysis [26]. In the final model, variables with p-values < 0.05 were considered as statisti-
cally significant predictors. We used the adjusted hazard ratios (AHR) with their 95%
confidence intervals and p-values to measure the strength of association and identify statisti-
cally significant predictors.
Ethics considerations
Ethical letter was obtained from the Ethical Review Committee of College of Health Science,
Debre Markos University. A permission letter was also written from the hospital general man-
ager to HIV-care clinic focal person. As this was a retrospective study, informed consent from
research participants was not feasible. Since the research was done by reviewing medical rec-
ords, the individual patients were not subjected to any harm as far as confidentiality is kept.
All collected data were coded and locked in a separate room, and computer data were secured
by a personal password to maintain privacy. Lastly, names and unique ART numbers were not




Among 466 retrieved HIV-infected children records, 58 (12.4%) were excluded due to incom-
pleteness. Then, 408 HIV-infected children’s records were considered for the final analysis.
More than half (54.7%) were males, and nearly two-thirds (67.7%) were from urban areas. The
mean age of participants at ART initiation was 6.9 years (SD: ±3.7 years), and the mean age of
caregivers was 33.5 years (SD: ±9.5 years). Moreover, more than half (53.7%) of the parents
were alive. Furthermore, about 66.6% of the children disclosed their HIV status, and the
majority (85.5%) of children were from the family of orthodox religious followers (Table 1).
Clinical, immunological, and nutritional characteristics of the children
More than half (52.7%) of the children had opportunistic infections (OIs) at ART initiation.
About 52% of the study participants were classified as mild disease stage (WHO stage I and II).
Nearly two-thirds (67.6%) of the children had CD4 counts or percentage above the threshold,
and only 11.5% of the study children were anemic (Hgb< 10mg/dl). The majority (90.7%) of
study participants started on NVP or EFV based ART drugs. More than half (60.8%) of the
participants had ever taken past OI prophylaxis. Moreover, more than three-quarters (78.8%)
of the children had good ART drug adherence in the last three months of ART follow-up. Fur-
thermore, about 49.3%, 51.7%, and 75.5% of the children were underweight, stunted, and
wasted, respectively (Table 2).
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Incidence of loss to follow-up
In this study, the participants were followed for a minimum of two months and a maximum of
136 months. At the end of follow-up, 17.1% (95% CI: 13.7, 21.1%) of the children were LTFU
from ART care. The total follow-up time of the entire cohort was 18,755 child-months of
Table 1. Sociodemographic characteristics of HIV-infected children receiving ART at Debre-Markos Referral
Hospital, Northwest Ethiopia, 2019.




Age of the child (in months)
0–35 month 63 15.5
36–96 month 207 50.7





Both mother and father alive 219 53.7
One or both died 189 46.3
Age of the caregiver
18–24 year 51 12.5
25–34 year 198 48.5
35–44 year 113 27.7
� 45 year 46 11.3




Educational status of the caregiver
Unable to read and write 148 36.3
Able to read and write 260 63.7




House wife 36 8.8
Daily laborer 89 21.8
Merchant 69 16.9
Child HIV status disclosure (180)
Yes 120 66.6
No 60 33.4
Religion of the caregiver
Orthodox 349 85.5
Others 59 14.5
Relation of caregiver for the child
Parent 348 85.3
Other guardians 60 14.7
https://doi.org/10.1371/journal.pone.0239013.t001
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Table 2. Clinical, immunological, and nutritional characteristics of HIV infected children receiving ART at
Debre-Markos Referral Hospital, Northwest Ethiopia, 2019.













Stage I and II 212 52.0
Stage III and IV 196 48.0
CD4 counts or CD4% at baseline
Below the threshold 132 32.4
Above the threshold 276 67.6
Level hemoglobin
Anemic (< 10 mg/dl) 47 11.5





EFV or NVP based 370 90.7





Immunologic or Clinical 341 83.6
Test and treat 67 16.4
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observation. The incidence density of LTFU among HIV-infected children in this study was
4.5 (95% CI: 3.5, 5.7) per 100 child-years of observation. The incidence rate of LTFU within
the first year of ART initiation was 8.2 (95% CI: 5.7, 11.7) per 100 child-years of observation,
whereas the incidence rate of LTFU after one year of ART initiation was 3.3 (95% CI: 2.6, 4.6)
months per 100 child-years of observation. The mean survival time of the entire follow-up was
108.8 months (95% CI: 103.1, 114.5 months) (Fig 1).
Table 2. (Continued)







Fig 1. The overall Kaplan-Meier survival curve of LTFU among HIV-infected children receiving ART at Debre-Markos Referral Hospital, Northwest Ethiopia,
2019.
https://doi.org/10.1371/journal.pone.0239013.g001
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Kaplan-Meier survival curves for different categorical predictors
The survival function of residence and ART drug adherence was compared using a generalized
log rank test. Accordingly, the mean survival time of HIV-infected children receiving ART
from urban areas was 119 months (95% CI: 113.1, 124.9 months); however, the mean survival
time of HIV-infected children receiving ART from rural areas was 84.4 months (95% CI: 74.0–
94.8 months). This difference was statistically significant (p-value < 0.001) (Fig 2).
The mean survival time of HIV infected children receiving ART who had good ART drug
adherence was 115.1 months (95% CI: 109.0, 121.2 months); however, the mean survival time of
HIV infected children receiving ART who had fair or poor ART drug adherence was 87.7 months
(95% CI: 75.3, 99.9 months). This difference was statistically significant (p-value< 0.001) (Fig 3).
Predictors of loss to follow-up
Ten variables (p-value < 0.25) were selected for the multivariable cox-regression analysis. In
the multivariable analysis, only four variables were found to be statistically significant predic-
tors of LTFU. Accordingly, the hazard of LTFU among HIV-infected children from rural areas
Fig 2. Kaplan-Meier survival curves to compare LTFU among HIV-infected children receiving ART between rural and urban areas at Debre-Markos Referral
Hospital, Northwest Ethiopia, 2019.
https://doi.org/10.1371/journal.pone.0239013.g002
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was 3.2 times (95% CI: 2.0, 5.3) higher than those who were from urban areas. Additionally,
the hazard of LTFU among HIV-children who had fair/poor ART drug adherence was 2.3
times (95% CI: 1.4, 3.8) higher as compared to those who had good ART drug adherence prior
to three months of last observation. Furthermore, the hazard of LTFU among HIV-infected
children started ART with test and treat criteria was 2.7 times (95% CI: 1.4, 5.5) higher than
those who started by immunologic and clinical criteria. Finally, the hazard of LTFU among
children who took PI-based ART regimens was 2.2 fold (95% CI: 1.1, 4.4) higher as compared
to those who took NNRTI based ART regimens (EFV and NVP based) (Table 3). The good-
ness of fit for the cox-proportional hazard model was assessed using a Cox-Snell residual test.
The graph suggested that the final model fits the data very well (Fig 4).
Discussion
Nowadays, LTFU among HIV-infected children receiving ART has become a significant pub-
lic health problem, negatively affecting the treatment outcomes. Therefore, we conducted this
Fig 3. Kaplan-Meier survival curves to compare LTFU among HIV-infected children receiving ART between good and fair or poor ART drug adherence at
Debre-Markos Referral Hospital, Northwest Ethiopia, 2019.
https://doi.org/10.1371/journal.pone.0239013.g003
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retrospective follow-up study to determine the incidence and predictors of LTFU among HIV-
infected children receiving ART at Debre Markos Referral Hospital. At the end of follow-up,
about 17.1% (95% CI: 13.7, 21.1%) of HIV-infected children lost from ART care. The inci-
dence density of LTFU in this study was estimated to be 4.5 (95% CI: 3.5, 5.7) per 100 child-
years of observation. Our finding is in line with studies done in South Africa (5.0 per 100
child-years) [27], Myanmar (4.7 per 100 child-years) [28], and Asia and Africa (4.1 per 100
child-years) [29]. Conversely, our finding is much lower than studies conducted in India (14.4
per 100-child years) [30], South Africa (10.8 per 100 child-years) [31], Tanzania (18.2 per
100-child years) [32], multicountry study (14.2 per 100-child years) [33], Malawi (12.6 per-100
child-years) [19], and Ethiopia (6.22 per 100 child-years) [11].
The above variations could be explained by differences in sample size, study setting, and
measurement variability in LTFU. The lower incidence rate of LTFU in this study might be
Table 3. Bi-variable and multivariable Cox regression analysis to identify the predictors of LTFU among HIV-infected children receiving ART at Debre-Markos
Referral Hospital, Northwest Ethiopia, 2019.
Variables Survival status CHR (95%CI) AHR (95%CI)
Lost Censured
Residence
Urban 28 248 1 1
Rural 42 90 3.6(2.3, 5.9) 3.2(2.0, 5.3)��
Religion of the caregiver
Orthodox 66 283 1 1
Others 4 55 0.31(0.1, 0.9) 0.5 (0.2, 1.5)
Relation of caregiver to the child
Parent 64 284 1 1
Other guardians 6 54 0.5(0.2, 1.1) 1.1(0.4, 2.8)
ART drug adherence
Good 40 281 1 1
Fair/poor 30 57 2.6(1.6, 4.1) 2.7(1.4, 5.5)��
ART eligibility criteria
Immunologic and clinical 55 286 1 1
Test and treat 15 52 2.6(1.4, 4.6) 2.7(1.4, 5.5) ��
Baseline ART regimen
NVP and EFV based 59 311 1 1
PI based 11 27 3.8(1.9, 7.3) 2.2(1.1, 4.4)��
WHO clinical staging
Stage I and II 31 181 1 1
Stage III and IV 39 157 1.3 (0.8, 2.2) 1.2 (0.7, 2.1)
CD4 counts
Below the threshold 43 233 1 1
Above the threshold 27 103 1.5(0.9, 2.4) 1.5(0.8, 2.6)
Wasting
Wasted 47 261
Normal 23 77 1.5(0.9, 2.5) 1.3(0.8, 2.2)
OI prophylaxis given
Yes 28 200 1 1
No 22 138 0.7(0.4–1.2) 0.8(0.47, 1.4)
��significant variables in the multivariable analysis.
https://doi.org/10.1371/journal.pone.0239013.t003
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due to the different interventions implemented by the Ethiopian government, including
adherence support through phone calls, case tracing through a home-to-home visit, and proac-
tive use of community health workers. Another possible justification might be due to the dif-
ference in length of follow-up. Our study had relatively longer follow-up time (14 years)
compared to previous studies conducted in SSA [19, 28, 31]. A further explanation for the vari-
ations could be due to differences in the characteristics of included participants. In this study,
more than half (52%) of the study participants were classified as WHO stage I and II; however,
about 73.2% of the study participants included in a study from South Africa were classified as
WHO stage III and IV [27]. Evidence suggests that HIV-infected children classified as severe
disease stage (WHO stage III and IV) at ART initiation were more prone to LTFU as com-
pared to those children classified as WHO stage I and II [11, 31].
This study found that the incidence rate of LTFU within one year of ART initiation was 8.2
(95%, CI: 5.7, 11.7) per-100 child years of observation. However, the incidence of LTFU after
one year of ART initiation was 3.3 (95% CI: 2.6, 4.6) per 100 child-years observation. A high
rate of LTFU in the early ART phase was observed. This finding is comparable with studies
Fig 4. Assessment of the model fitness using Cox-Snail residual test among HIV-infected children receiving ART at Debre-Markos Referral Hospital, Northwest
Ethiopia, 2019.
https://doi.org/10.1371/journal.pone.0239013.g004
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conducted in South Africa, which showed that LTFU was higher in the first six months of ART
follow-up [28, 31]. Supportive findings were also reported from studies done in multicountry
based studies [9, 33], Tanzania [32], and Ethiopia [11].
HIV-infected children from rural areas were at higher risk of LTFU as compared to their
urban counterparts. This finding is in agreement with other previous studies conducted in
Asia and Africa [29], Ethiopia [11], and Malawi [19]. The possible justification could be due to
the fact that children living in rural areas travel long distances to get access to ART. Studies
suggested that patients living far from a health facility had a greater risk of LTFU [34, 35].
Moreover, children living in rural areas could have difficulties to access favorable transporta-
tion; as a result, they could miss their appointments. Additionally, caregivers maybe forget to
bring their children to the ART clinic at each visit. Lastly, the caregiver’s level of education has
a significant effect on LTFU because most rural mothers are uneducated. As a result, they com-
monly seek faith healing or traditional therapies [36].
This study also indicated that children who had fair or poor ART drug adherence were at
higher risk of LTFU compared to those who had good adherence. It is well understood that the
relationship between ART drug adherence and LTFU is bidirectional. The common reasons
for poor ART adherence among people living with HIV are the use of traditional/herbal medi-
cine, dissatisfaction with healthcare services, depression, discrimination and stigmatization,
and poor social support [37]. These factors are also directly related to the risk of LTFU. The
other common reason for LTFU is fear of ART side-effects. Lastly, if patens do not take their
drug properly (have poor ART adherence), they don’t have good improvements in the early
ART phase. This leads to early treatment failure and the rapid development of drug resistance.
This study also found that children who started ART based on the test and treat approach
were at higher risk of LTFU as compared to those who started ART based on immunologic
(CD4 counts) or clinical (WHO staging) criteria. Despite WHO recommends that HIV-posi-
tive patients can start ART within the seven days after HIV-confirmation, evidence from an
observational study revealed that starting ART on the same day of HIV diagnosis increases the
risk of LTFU [38]. According to the WHO recommendation, higher LTFU is documented as
the main weakness of the test and treat approach [39]. Another possible explanation could be
due since starting ART at the same day of HIV confirmation without intensive counselling
and adequate preparation may lead to fear of stigma and discrimination and finally leads to
LTFU in the early ART phase.
Finally, children who started PI-based ART regimens were at higher risk of LTFU as com-
pared to those who started non-nucleoside reverse transcriptase inhibitors (Nevirapine or Efa-
virenz) based ART regimens. This finding contradicts a previous study done in Myanmar [28].
This variation could be due to the baseline differences between study participants at ART initi-
ation, leading to the prescription of PI-based regimens. The actual effects of PI-based regimens
on better treatment outcomes would need further follow-up studies.
Potential limitations of the study
This study has some constraints that must be considered before interpreting results. As the
study used secondary data, some important variables such as viral load, micronutrient defi-
ciency, and immunization status of the child were not included. This study was also unable
to ascertain the reasons for and outcomes of LTFU due to incomplete documentation.
Patients recorded as LTFU might be died or started ART in another health institutions.
Therefore, the actual LTFU might be overestimated in this study. The study’s main strength
was conducted for a more extended period of follow-up time (14 years); this could increase
observation time.
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Conclusion
This study found that one in every six HIV-infected children lost form ART follow-up. Rela-
tively a lower rate of LTFU was observed as compared to previous studies reported in Ethio-
pian and other SSA countries. Moreover, a higher rate of LTFU was seen within the first year
of ART initiation. HIV-infected children from rural areas, having fair or poor ART drug
adherence, started ART based on test and treat approach, and taking PI-based ART regimens
were at higher risk of LTFU. Thus, particular emphasis and close follow-up must be given
within the first year of ART initiation. Moreover, tracing mechanisms should be strengthened
for children who are from rural areas. Furthermore, providing participatory advice and letting
them decide rather than enforcing to start ART immediately after HIV confirmation is highly
appreciated. Further prospective follow-up studies by considering viral load, child immuniza-
tion, and micronutrient deficiencies are highly recommended. Lastly, qualitative studies to
explore the reasons of LTFU are also recommended.
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